Skip to main content
Fig. 6 | Breast Cancer Research

Fig. 6

From: Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy

Fig. 6

Leronlimab enhances the cell death induced by doxorubicin, a DNA damage-inducing chemotherapy agent. a MDA-MB-231 cells were treated with 10 μg/ml of leronlimab combined with different dose of doxorubicin for 3 days. The MTT assay was used to determine the relative cell number. The relative absorbance is shown as a fraction of the untreated control. The normalization of leronlimab-treated cells was to leronlimab with no doxorubicin. In b, the cells were treated with maraviroc (100 mM) combined with different doses of doxorubicin, used as a positive control. Data are shown as mean ± SEM for N = 8

Back to article page
\